+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 271 Pages
  • February 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1882057
The global market for Overactive Bladder (OAB) Therapeutics was valued at US$1.3 Billion in 2024 and is projected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Overactive Bladder (OAB) Therapeutics - Key Trends and Drivers

The growth in the OAB therapeutics market is driven by several factors. Technological advancements in drug formulation and delivery systems are making treatments more effective and user-friendly, thereby driving demand. The aging global population, which is more susceptible to OAB, is significantly expanding the addressable market. Increased awareness and diagnosis rates of OAB, fueled by educational campaigns and improved diagnostic tools, are leading to higher treatment adoption. Additionally, the rising prevalence of lifestyle diseases such as diabetes and obesity, which are risk factors for OAB, is contributing to market growth. Pharmaceutical companies are investing heavily in research and development to introduce novel therapeutics with superior efficacy and safety profiles. The integration of digital health solutions is enhancing patient engagement and adherence to treatment regimens. Furthermore, favorable reimbursement policies and healthcare infrastructure improvements, particularly in emerging markets, are supporting market expansion. The collective impact of these factors is fostering robust growth in the OAB therapeutics market, ensuring better management and improved quality of life for affected individuals.

Several trends are shaping the landscape of OAB therapeutics. One significant trend is the shift towards personalized medicine, where treatments are tailored to the individual's genetic profile and specific symptoms, thereby enhancing treatment outcomes. Innovations in drug delivery systems, such as transdermal patches and extended-release formulations, are improving patient adherence by reducing the frequency of dosing and minimizing side effects. Additionally, the development of combination therapies that target multiple pathways involved in bladder control is gaining traction, offering more comprehensive symptom management. Digital health technologies, including mobile health applications and wearable devices, are increasingly being integrated into OAB management, enabling real-time symptom tracking and personalized treatment adjustments. Furthermore, there is growing interest in non-pharmacological interventions, such as neuromodulation techniques, which offer alternative treatment options for patients who do not respond well to medication.

Overactive Bladder (OAB) is a prevalent urological condition characterized by a sudden, involuntary contraction of the muscle in the wall of the urinary bladder, leading to an urgent need to urinate. This condition affects millions of people worldwide, with a higher incidence among the elderly and women. OAB significantly impacts the quality of life, causing social, psychological, and physical distress. Therapeutics for OAB include a range of pharmacological treatments such as antimuscarinics, beta-3 adrenergic agonists, and newer modalities like botulinum toxin injections. These treatments aim to relax the bladder muscle, reduce urinary frequency, and manage symptoms effectively. The market for OAB therapeutics is evolving, with ongoing research focused on developing drugs with better efficacy, fewer side effects, and improved patient compliance.

Report Scope

The report analyzes the Overactive Bladder (OAB) Therapeutics market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.

Segments

Pharmacotherapy (Anticholinergics, Neurostimulation, Botox, Mirabegron).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Anticholinergics segment, which is expected to reach US$614.7 Million by 2030 with a CAGR of a 3.1%. The Neurostimulation segment is also set to grow at 2.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $340.7 Million in 2024, and China, forecasted to grow at an impressive 4.7% CAGR to reach $290.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Overactive Bladder (OAB) Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Overactive Bladder (OAB) Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Overactive Bladder (OAB) Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Allergan PLC, Astellas Pharma, Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo Pharmaceuticals, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 34 companies featured in this Overactive Bladder (OAB) Therapeutics market report include:

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Overactive Bladder (OAB) Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Aging Global Population Expands Addressable Market Opportunity for OAB Therapeutics
  • Innovations in Drug Delivery Systems Propel Growth in OAB Treatment Solutions
  • Personalized Medicine Throws the Spotlight on Tailored OAB Therapeutic Approaches
  • Advances in Neuromodulation Techniques Strengthen Business Case for Non-Pharmacological Interventions
  • Increased Awareness and Diagnosis Rates Drive Adoption of OAB Treatments
  • Rising Prevalence of Lifestyle Diseases Generates Demand for OAB Therapeutics
  • Integration of Digital Health Technologies Accelerates Demand for Real-Time Symptom Management
  • Development of Combination Therapies Enhance Comprehensive Symptom Control
  • Improved Diagnostic Tools Enhanced Early Detection and Treatment
  • Technological Advancements in Extended-Release Formulations Sustain Growth in OAB Market
  • Consumer Preference for Non-Invasive Treatments Expands Market for Alternative Therapies
  • Economic Burden of Untreated OAB Fuels Demand for Effective Management Solutions
  • Impact of Telemedicine Services on Enhancing Patient Access and Treatment Compliance
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Overactive Bladder (OAB) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Neurostimulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Botox by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Mirabegron by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 18: USA Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 19: USA 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 21: Canada Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 22: Canada 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
JAPAN
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • Table 23: Japan Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 24: Japan Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 25: Japan 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
CHINA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • Table 26: China Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 27: China Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 28: China 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
EUROPE
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • Table 29: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 31: Europe 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • Table 32: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 34: Europe 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
FRANCE
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • Table 35: France Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 36: France Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 37: France 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
GERMANY
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • Table 38: Germany Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 39: Germany Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 40: Germany 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
ITALY
  • Table 41: Italy Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 42: Italy Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 43: Italy 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
UNITED KINGDOM
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • Table 44: UK Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 45: UK Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 46: UK 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
SPAIN
  • Table 47: Spain Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 48: Spain Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 49: Spain 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
RUSSIA
  • Table 50: Russia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 51: Russia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 52: Russia 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
REST OF EUROPE
  • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 54: Rest of Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 55: Rest of Europe 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
ASIA-PACIFIC
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 58: Asia-Pacific 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 61: Asia-Pacific 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2015, 2025 & 2030
AUSTRALIA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

Table Information